NASDAQ:NRIX
Nurix Therapeutics, Inc. Stock News
$14.95
+1.01 (+7.25%)
At Close: May 14, 2024
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
06:49pm, Thursday, 07'th Apr 2022
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the st
Nurix Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 09'th Mar 2022
SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. S
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinica
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
09:01pm, Thursday, 10'th Feb 2022 GlobeNewswire
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET.
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
04:01pm, Thursday, 10'th Feb 2022
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. S
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
06:27pm, Thursday, 27'th Jan 2022
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the
Nurix Therapeutics (NRIX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
07:28pm, Monday, 24'th Jan 2022 Seeking AlphaEndowment Pmf Master Fund, L.p. Buys Compass Inc, Sells Nurix Therapeutics Inc, Upstart ...
11:38am, Saturday, 11'th Dec 2021 GuruFocus
Related Stocks: COMP , NRIX , UPST , NEO ,
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of Buy from Analysts
12:38am, Monday, 06'th Dec 2021 Dakota Financial News
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have received an average rating of Buy from the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages []
Gwenn Hansen Sells 400 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock
02:52pm, Friday, 03'rd Dec 2021 Transcript Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 400 shares of the stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $29.13, for a total transaction of $11,652.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Gwenn Hansen also []
Brokerages Expect Nurix Therapeutics, Inc. (NASDAQ:NRIX) Will Announce Quarterly Sales of $16.24 Million
08:46pm, Thursday, 25'th Nov 2021 Transcript Daily
Analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will report $16.24 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Nurix Therapeutics’ earnings, with the highest sales estimate coming in at $35.46 million and the lowest estimate coming in at $8.80 million. Nurix Therapeutics posted sales of […]
Zacks: Analysts Anticipate Nurix Therapeutics, Inc. (NASDAQ:NRIX) Will Announce Earnings of -$0.65 Per Share
08:46pm, Thursday, 25'th Nov 2021 Dakota Financial News
Analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will post ($0.65) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Nurix Therapeutics’ earnings, with estimates ranging from ($0.79) to ($0.37). Nurix Therapeutics reported earnings per share of ($0.51) during the same quarter last year, which suggests a […]
Nurix Therapeutics (NRIX) Investor Presentation - Slideshow
01:23pm, Tuesday, 23'rd Nov 2021 Seeking AlphaNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Squarepoint Ops LLC
10:24am, Monday, 22'nd Nov 2021 Transcript Daily
Squarepoint Ops LLC lowered its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 33.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,558 shares of the companys stock after selling 5,250 shares during the period. Squarepoint Ops LLCs holdings in Nurix Therapeutics []